Loading company
Latest annual · FY2025
Millions- Total revenues
- 4
- Operating income
- (665)
- Net income
- (582)
- Free cash flow
- (346)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 13
- Operating income
- (130)
- Net income
- (111)
- Free cash flow
- (90)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +43.1%
- Revenue, 5 yearsFY2020 to FY2025
- +37.3%
- Net income, 5 yearsFY2020 to FY2025
- n/m
CRISPR Therapeutics AG (CRSP) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.5 million | $37.3 million | -90.6% | 10-K 2026-02-12 · proof |
| Operating income | -$664.6 million | -$466.6 million | 10-K 2026-02-12 · proof | |
| Net income | -$581.6 million | -$366.3 million | 10-K 2026-02-12 · proof | |
| Cash from operating activities | -$345 million | -$142.8 million | 10-K 2026-02-12 · proof | |
| Free cash flow | -$345.9 million | -$144.7 million | 10-K 2026-02-12 · proof | |
| Total assets | $2.3 billion | $2.2 billion | +1% | 10-K 2026-02-12 · proof |
| Total liabilities | $343.4 million | $310 million | +10.8% | 10-K 2026-02-12 · proof |
| Cash and cash equivalents | $347.6 million | $298.3 million | +16.5% | 10-K 2026-02-12 · proof |
- What was CRISPR Therapeutics AG (CRSP)'s revenue in fiscal 2025?
- CRISPR Therapeutics AG (CRSP) reported revenue of $3.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $37.3 million the year before (-90.6%). Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What was CRISPR Therapeutics AG (CRSP)'s operating income in fiscal 2025?
- CRISPR Therapeutics AG (CRSP) reported operating income of -$664.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$466.6 million the year before. Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What was CRISPR Therapeutics AG (CRSP)'s net income in fiscal 2025?
- CRISPR Therapeutics AG (CRSP) reported net income of -$581.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$366.3 million the year before. Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What was CRISPR Therapeutics AG (CRSP)'s cash from operating activities in fiscal 2025?
- CRISPR Therapeutics AG (CRSP) reported cash from operating activities of -$345 million for fiscal 2025 (the year ended Dec 31, 2025), against -$142.8 million the year before. Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What was CRISPR Therapeutics AG (CRSP)'s free cash flow in fiscal 2025?
- CRISPR Therapeutics AG (CRSP) reported free cash flow of -$345.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$144.7 million the year before. Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What are CRISPR Therapeutics AG (CRSP)'s total assets?
- As of Dec 31, 2025, CRISPR Therapeutics AG (CRSP) reported total assets of $2.3 billion, against $2.2 billion a year earlier (+1%). Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What are CRISPR Therapeutics AG (CRSP)'s total liabilities?
- As of Dec 31, 2025, CRISPR Therapeutics AG (CRSP) reported total liabilities of $343.4 million, against $310 million a year earlier (+10.8%). Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
- What are CRISPR Therapeutics AG (CRSP)'s cash and cash equivalents?
- As of Dec 31, 2025, CRISPR Therapeutics AG (CRSP) reported cash and cash equivalents of $347.6 million, against $298.3 million a year earlier (+16.5%). Source: the 10-K filed with the SEC on Feb 12, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CRSP&period_type=annual&limit=5"Information only, not investment advice.